Evidence map›Paper›PMID 17638091›Full record

ArticleInflammopharmacology1999

Persons and pathogens: consequences of co-existence.

M C Powanda

Abstract read
PubMed Publisher
In one paragraph

Article in Inflammopharmacology, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

M C PowandaM/P Biomedical Consultants LLC, 94941, Mill Valley, California, USA. mpbiomed@slip.net

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is considerable evidence that infectious agents may be a cofactor, or even the cause, of a panoply of chronic inflammatory diseases, as well as of some cancers and neurologic diseases. Examples are presented of the evidence for the thesis that infectious antecedents may underlie many inflammatory conditions and some of the diseases in which infections are postulated to be the precipitating factor.Given that infectious agents may give rise to an impressive array of chronic diseases, should we, therefore, consider alternative modes of treatment for such diseases which focus on the infectious antecedent rather than the consequent disease?With regard to therapy, are new classes of antibiotic/anti-inflammatory drugs needed? Or would preventive measures, such as better food handling and water treatment, along with a widespread campaign of prophylactic and therapeutic vaccines against the likely infectious agents, be a more cost effective approach to ameliorate or ablate the onset of a wide range of inflammatory diseases, cancers and neurologic diseases? Since this conference was primarily designed to discuss the safety and efficacy of NSAIDs, it is appropriate to ponder whether chronic/lifelong NSAID/aspirin intake may have value in preventing or treating chronic inflammatory and neurologic diseases as well as some cancers. There are studies that indicate that long term use of some NSAIDs including aspirin may reduce the likelihood of occurrence of some of these chronic diseases. We thus should ponder the potential risks and benefits of lifelong NSAID/aspirin intake. To that end we should ask what kind of a database should be established so that a valid estimate of the benefits versus the risks of extended, perhaps lifelong, use of a present or future NSAID(s) may be considered for the prevention of any given disease?

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.